Literature DB >> 31659807

A prospective study of psychological distress after prostate cancer surgery.

Stefano Occhipinti1, Leah Zajdlewicz2, Geoffrey D Coughlin3, John W Yaxley3, Nigel Dunglison3, Robert A Gardiner3,4,5,6, Suzanne K Chambers1,4,6,7.   

Abstract

BACKGROUND: Men treated for prostate cancer experience heightened psychological distress and have an increased risk of suicide. Management of this distress and risk is crucial for quality urological care.
OBJECTIVE: To identify risk indicators for poorer trajectories of psychological adjustment and health-related quality of life (QoL) after surgery for localised prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Patients were newly diagnosed with localised prostate cancer scheduled for surgical treatment. Patients were assessed at baseline (pre-surgery) and 6 weeks, 3 months, 6 months, 12 months, and 24 months post-surgery. MEASUREMENTS: Assessment measures included sociodemographics, domain-specific and health-related QoL, and psychological distress. Mixed effects regression models were used to analyse the data. RESULTS AND LIMITATIONS: A total of 233 patients provided data for this analysis (Mage = 60 years, standard deviation [SD] = 4.02; MPSA = 7.37 ng/mL). At baseline, the prevalence of high psychological distress was 28% reducing to 21% at 24 months. Before treatment, younger age, more comorbidities, and worse bowel function were related to greater psychological distress; and younger age and better urinary, sexual, and bowel function were related to better health-related QoL. By contrast, for changes over time, only bowel function was important with better bowel function predicting decreasing psychological distress for men.
CONCLUSIONS: Regular distress screening is indicated over the 24 months after surgery for localised prostate cancer. Care pathways for men with prostate cancer need also to respond to age-specific concerns and health problems associated with comorbidities in aging men. Focussed symptom control for bowel bother should be a priority.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  distress, longitudinal; oncology, prostatectomy; prostate cancer; quality of life

Mesh:

Year:  2019        PMID: 31659807     DOI: 10.1002/pon.5263

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  6 in total

1.  When experiencing a surgery: Gastrointestinal cancer patients' longitudinal trajectories in psychological stress and their association with quality of recovery.

Authors:  Gaorong Lv; Di Zhao; Guopeng Li; Meiling Qi; Xiaoling Dong; Ping Li
Journal:  Asia Pac J Oncol Nurs       Date:  2022-04-11

2.  Improved cancer coping from a web-based intervention for prostate cancer survivors: A randomized controlled trial.

Authors:  Erin K Tagai; Suzanne M Miller; Shawna V Hudson; Michael A Diefenbach; Elizabeth Handorf; Alicja Bator; Allison Marziliano; Alexander Kutikov; Simon J Hall; Manish Vira; Michael Schwartz; Issac Yi Kim; Sung Kim
Journal:  Psychooncology       Date:  2021-04-28       Impact factor: 3.955

Review 3.  Psychological Interventions Prior to Cancer Surgery: a Review of Reviews.

Authors:  Chloe Grimmett; Nicole Heneka; Suzanne Chambers
Journal:  Curr Anesthesiol Rep       Date:  2022-01-31

4.  Personal Perspectives: Having a Prostatectomy and the Role of the Cancer Specialist Nurse.

Authors:  Simon D Taylor-Robinson; Kathy Dykes; Bethan Hawkes
Journal:  Int J Gen Med       Date:  2020-10-19

5.  Current Mental Distress Among Men With a History of Radical Prostatectomy and Related Adverse Correlates.

Authors:  Gabriela Ilie; Joshua White; Ross Mason; Ricardo Rendon; Greg Bailly; Joseph Lawen; David Bowes; Nikhilesh Patil; Derek Wilke; Cody MacDonald; Robert Rutledge; David Bell
Journal:  Am J Mens Health       Date:  2020 Sep-Oct

6.  Prostate cancer survivorship essentials framework: guidelines for practitioners.

Authors:  Jeff Dunn; Anna Green; Nicholas Ralph; Robert U Newton; Andrew Kneebone; Mark Frydenberg; Suzanne K Chambers
Journal:  BJU Int       Date:  2020-08-18       Impact factor: 5.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.